QoL better with bladder Ca immunotherapy vs. chemo – ModernMedicine
|
QoL better with bladder Ca immunotherapy vs. chemo
ModernMedicine Chicago—Patients treated with pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma (UC) following platinum-based chemotherapy maintain better health-related quality of life (HRQoL) than their counterparts receiving … |
|
COX-2 Inhibitors Can Improve Response to Immunotherapy of Some Cancer Tumors
Oncology Nurse Advisor Many tumor cells are resistant to immunotherapy due to IDO1 expression. In adaptive resistance, the tumor cells starts to produce IDO1 — which is associated with inflammation and T-cell infiltration — upon T-cell attack. In intrinsic resistance, the … COX-2 inhibitors may reverse IDO1-mediated immunosuppression in some cancersMedical Xpress |
|
TransDisciplinary University Brings Together the Best Minds to Deliberate over the Promise and Problems of Synthetic …
Business Wire India (press release) Speaking on the occasion, Dr. Balakrishna Pisupati, Vice-chancellor, TDU, said, “In less than a decade, Synthetic Biology has managed to garner the attention of top technologists, researchers and policy makers worldwide. Countries like Australia and … |
Genetic Engineering & Biotechnology News |
CRISPR Structure Data Reveal How Cas Enzymes Choose Target
Genetic Engineering & Biotechnology News New data from Jennifer Doudna, Ph.D., co-pioneer of the CRISPR/Cas9 genome-editing technology, and her research group at the University of California, Berkeley show that for bacterial adaptive immunity to achieve site-selective expansion, the CRISPR … This Week in ScienceGenomeWeb |
|
Alligator, Aptevo Partner on Bispecific Cancer Immunotherapy …
Genetic Engineering & Biotechnology News (blog) Swedish firm Alligator Bioscience and Seattle-based Aptevo Therapeutics have agreed to co-develop ALG.APV-527, a bispecific antibody for tumor-directed … Alligator Bioscience AB: Aptevo Therapeutics and Alligator …GlobeNewswire (press release) |
|
Alligator, Aptevo Partner on Bispecific Cancer Immunotherapy …
Genetic Engineering & Biotechnology News (blog) Swedish firm Alligator Bioscience and Seattle-based Aptevo Therapeutics have agreed to co-develop ALG.APV-527, a bispecific antibody for tumor-directed … Alligator Bioscience AB: Aptevo Therapeutics and Alligator …GlobeNewswire (press release) |
|
A vibrant synthetic biology ecosystem has developed in the UK – promising new jobs and valuable technology
PharmiWeb.com (press release) London, UK, 21st July 2017 / Sciad Newswire / A survey of synthetic biology company start-ups in the UK is published today by SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology. The study reveals a vibrant ecosystem … |